{"id":"https://openalex.org/W4380149277","doi":"https://doi.org/10.1016/j.jval.2023.03.2235","title":"SA19 Real-World Targeted Literature Review of Intolerance with Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia","display_name":"SA19 Real-World Targeted Literature Review of Intolerance with Tyrosine Kinase Inhibitor Treatment for Chronic Myeloid Leukemia","publication_year":2023,"publication_date":"2023-06-01","ids":{"openalex":"https://openalex.org/W4380149277","doi":"https://doi.org/10.1016/j.jval.2023.03.2235"},"language":"en","primary_location":{"id":"doi:10.1016/j.jval.2023.03.2235","doi":"https://doi.org/10.1016/j.jval.2023.03.2235","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2023.03.2235","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301523023355/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"http://www.valueinhealthjournal.com/article/S1098301523023355/pdf","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":null,"display_name":"K. Jadhav","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"K. Jadhav","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"A. Damon","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A. Damon","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088771820","display_name":"David T. Yang","orcid":"https://orcid.org/0000-0002-9488-1704","observed_orcids":["https://orcid.org/0000-0002-9488-1704"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Yang","raw_affiliation_strings":["Analysis Group, Inc., Montr\u00e9al, QC, Canada","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montr\u00e9al, QC, Canada","institution_ids":[]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5085492465","display_name":"Dominick Latr\u00e9mouille-Viau","orcid":"https://orcid.org/0000-0002-8565-9220","observed_orcids":["https://orcid.org/0000-0002-8565-9220"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Latremouille-Viau","raw_affiliation_strings":["Analysis Group, Inc., Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montr\u00e9al, QC, Canada","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022308730","display_name":"Deok\u2010Hwan Yang","orcid":"https://orcid.org/0000-0002-8167-8520","observed_orcids":["https://orcid.org/0000-0002-8167-8520","https://orcid.org/0000-0003-2830-9889"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"D. Yang","raw_affiliation_strings":["Analysis Group, Inc., Montr\u00e9al, QC, Canada","Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montr\u00e9al, QC, Canada","institution_ids":[]},{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109084559","display_name":"A. Gu\u00e9rin","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"A Gu\u00e9rin","raw_affiliation_strings":["Analysis Group, Inc., Montr\u00e9al, QC, Canada"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Analysis Group, Inc., Montr\u00e9al, QC, Canada","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049173479","display_name":"Islam Mohamad Sadek","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"I. Sadek","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":3200,"currency":"USD","value_usd":3200},"apc_paid":null,"fwci":null,"has_fulltext":true,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"26","issue":"6","first_page":"S400","last_page":"S400"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11215","display_name":"Chronic Myeloid Leukemia Treatments","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11157","display_name":"Chronic Lymphocytic Leukemia Research","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10804","display_name":"Health Systems, Economic Evaluations, Quality of Life","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2002","display_name":"Economics and Econometrics"},"field":{"id":"https://openalex.org/fields/20","display_name":"Economics, Econometrics and Finance"},"domain":{"id":"https://openalex.org/domains/2","display_name":"Social Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/chronic-myeloid-leukemia","display_name":"chronic myeloid leukemia","score":0.9990000128746033},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":1.0},{"id":"https://openalex.org/keywords/drug-intolerance","display_name":"drug intolerance","score":0.7649999856948853},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.6729999780654907},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.6039999723434448},{"id":"https://openalex.org/keywords/clinical-outcomes","display_name":"clinical outcomes","score":0.7379999756813049},{"id":"https://openalex.org/keywords/economic-outcomes","display_name":"economic outcomes","score":0.9399999976158142},{"id":"https://openalex.org/keywords/humanistic-outcomes","display_name":"humanistic outcomes","score":0.9340000152587891},{"id":"https://openalex.org/keywords/real-world-evidence","display_name":"real-world evidence","score":0.8899999856948853}],"concepts":[{"id":"https://openalex.org/C2778729363","wikidata":"https://www.wikidata.org/wiki/Q11688946","display_name":"Myeloid leukemia","level":2,"score":0.8536988496780396},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7891381978988647},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.707331657409668},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.6246578693389893},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.43421903252601624},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4221770465373993},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.08318769931793213},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.055421680212020874}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.jval.2023.03.2235","doi":"https://doi.org/10.1016/j.jval.2023.03.2235","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2023.03.2235","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301523023355/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.1016/j.jval.2023.03.2235","doi":"https://doi.org/10.1016/j.jval.2023.03.2235","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.jval.2023.03.2235","pdf_url":"http://www.valueinhealthjournal.com/article/S1098301523023355/pdf","source":{"id":"https://openalex.org/S678965","display_name":"Value in Health","issn_l":"1098-3015","issn":["1098-3015","1524-4733"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["abdc-a","anvur-class-a","anvur-scientific","cwts-core","dongbi-a","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Value in Health","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4380149277.pdf","grobid_xml":"https://content.openalex.org/works/W4380149277.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2952141298","https://openalex.org/W3095314266","https://openalex.org/W4405748861","https://openalex.org/W4405040746","https://openalex.org/W1527252739","https://openalex.org/W4389885856","https://openalex.org/W3172509554","https://openalex.org/W7095729069","https://openalex.org/W2327637245","https://openalex.org/W7123577698"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-06-11T00:00:00"}